Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 408 of 6351
-
Could a One-Time treatment give kidney cancer patients a year off drugs?
Disease control Not yet recruitingThis is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkp…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare leukemia: drug cocktail shows promise
Disease control Not yet recruitingAcute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New lung cancer drug shows promise in early trial
Disease control Recruiting nowThis study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can dupilumab keep COPD patients out of the hospital?
Disease control Not yet recruitingThis study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up…
Phase 4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to tame dangerous immune reaction in myeloma therapy
Disease control Recruiting nowThe purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Not yet recruitingThis is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF pati…
Phase 2 • Sponsor: InnovStone Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Self-Sampling and digital colposcopy could speed up cervical cancer detection
Diagnosis Not yet recruitingThe PRIORITY study is a prospective, multicenter observational study designed to evaluate an integrated diagnostic model combining extended molecular self-sampling and digital colposcopy supported by telemedicine for the prioritization of women at risk of cervical cancer. The st…
Sponsor: Pontificia Universidad Catolica de Chile • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy targets tough lung cancers
Disease control Not yet recruitingThis study is an open, multicenter, phase II clinical study for evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ALK202 for injection combined with different drugs in participants with locally advanced or metastatic NSCLC. The study consists of two…
Phase 2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Sound waves and bubbles take on stubborn joint infections
Disease control Recruiting nowPatients with an infected knee replacement will receive their standard of care surgical treatment of the infection, with and without additional ultrasound microbubble treatment (randomly divided 50/50 in the active and control groups). Subjects in the active group will receive a …
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo aims to shrink advanced stomach tumors
Disease control Not yet recruitingThis study is a multicenter,open-label,randomized, phase II clinical study conducted in China. The purpose of this study is to evaluate the efficacy of SKB315 plus PD-1 inhibitor ±capecitabine in patients with Unresectable Locally Advanced or Metastatic Gastric or Gastroesophagea…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Triple-Drug attack aims to shrink cervical cancer tumors
Disease control Not yet recruitingThis study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Phase 2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control Not yet recruitingThe goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB…
Phase 1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Inhaled drug could offer new hope for lung scarring disease
Disease control Recruiting nowThis trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID…
Phase 2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo aims to boost response in Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn if adding savolitinib to cetuximab plus FOLFOX chemotherapy works as a first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer, and to evaluate its safety. The main questions it aims to answer are: Does t…
Phase 1/2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Heart attack patients may get a powerful new tool to slash cholesterol
Disease control Not yet recruitingThis study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental fusion protein aims to re-engage immune system against tough esophageal cancer
Disease control Not yet recruitingEffective later-line treatment options remain an unmet medical need for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease has progressed after prior immunotherapy, particularly given the widespread use of immunotherapy in the first-line setting. This …
Phase 2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Three-Drug cocktail aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study is a single-center, prospective, open-label exploratory clinical study to assess the efficacy and safety of kumorixilib combined with capecitabine and letrozole as neoadjuvant therapy in patients with HR+/HER2- stage II-III invasive breast cancer. The study plans to en…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Robotic surgery from miles away: could remote operations match On-Site care?
Disease control Not yet recruitingThis study will compare remote robotic surgery with on-site robotic surgery for patients who need surgery for diseases of the liver, bile duct, gallbladder, or pancreas. Remote robotic surgery means that an experienced surgeon controls the robotic surgical system from a different…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can Ultrasound-Guided shock waves dissolve shoulder calcium deposits?
Disease control Recruiting nowCalcific tendinitis of the shoulder is a debilitating musculoskeletal condition that significantly impacts the working-age population, typically those between 30 and 60 years of age. Accounting for approximately 7- 17% of shoulder pain complaints, it is characterized by the patho…
Sponsor: Taipei Medical University WanFang Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can imagining movement supercharge robot hand therapy for stroke recovery?
Disease control CompletedLoss of upper extremity and particularly hand function after stroke reduces independence in daily activities such as eating, dressing, and personal care. Robot-assisted hand rehabilitation provides repetitive, intensive, and task-oriented practice that supports motor learning, de…
Sponsor: Uskudar University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC